Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $38M (down 3.8% year over year) with net income of −$38M.
Q3 2025 key financials · XBRL
- Revenue
- $38M
- −3.8% YoY · −3.3% QoQ
- Net income
- −$38M
- +37.4% YoY · +9.4% QoQ
- Operating margin
- -101.1%
- Gross margin
- 41.4%
- EPS (diluted)
- −$0.12
- +45.5% YoY · +7.7% QoQ
Source: XBRL data from the PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q3 2025 10-Q on SEC EDGAR. USD.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Nine-month revenue $115.4M vs $114.8M YoY
- Gross profit $29.2M vs $27.2M YoY
- Consumables revenue $60.3M vs $51.6M; instrument revenue $36.5M vs $50.5M
- Cash, equivalents, and investments $298.7M vs $389.9M at December 31, 2024
- Strategy focused on Vega rollout, SPRQ chemistry adoption, product launches, and clinical sequencing growth
Risk Factors
- Newly added tariff risk triggered by U.S. government measures and trading-partner responses
- Most materially updated commercialization risk: Vega launch and Revio transitions may create obsolete inventory and firm-commitment losses
- Regulatory risk from evolving privacy, ethical, legal, and social concerns surrounding genetic testing
- Market risk from slower customer capital-equipment purchases amid uncertain economic conditions
- Financial risk from $15.0 million of impairment charges during nine months ended September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.